<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02101866</url>
  </required_header>
  <id_info>
    <org_study_id>BTA798-103</org_study_id>
    <nct_id>NCT02101866</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Oral Bioavailability of Single Doses of Two Vapendavir Drug Formulations in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Single-Center, Open-Label, Two-Period, Two-Sequence, Crossover, Comparative Study to Compare the Oral Bioavailability of Single Doses of Two Vapendavir Drug Product Formulations in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biota Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vaxart</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1 study aims to determine the oral bioavailability of a single dose of a new
      vapendavir tablet formulation and compare it to that of the previous vapendavir capsule
      formulation. The safety of both drug products will also be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systemic exposure profile of a single dose of a vapendavir 300 mg tablet compared to the exposure profile following a single dose of two 132 mg vapendavir capsules</measure>
    <time_frame>maximum up to 46 days</time_frame>
    <description>PK and statatistical analyses will be performed to determine the Primary Outcome Measure</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Vapendavir 300 mg tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vapendavir 300 mg tablet single dose with up to 7 day washout period followed by two vapendavir 132 mg capsules single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Two Vapendavir 132 mg capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two Vapendavir 132 mg capsules single dose with up to 7 day washout period followed by Vapendavir 300 mg tablet single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vapendavir 300 mg tablet</intervention_name>
    <description>tablet - single dose</description>
    <arm_group_label>Vapendavir 300 mg tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vapendavir 132 mg capsules</intervention_name>
    <description>2 capsules - single dose</description>
    <arm_group_label>Two Vapendavir 132 mg capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be male or female between 18 and 55 years of age (inclusive) with BMI between 18
             and 30 kg/m2 (inclusive), and weight â‰¥50 kg at the time of screening

          -  Capable of giving written informed consent

          -  Subject is able to understand and comply with the protocol requirements, instructions
             and restrictions

          -  Healthy on the basis of physical examination, medical history, medication usage, VS,
             ECGs, and clinical laboratory tests

          -  Female subjects must be of non-childbearing potential

          -  Male subjects must agree to use a double barrier method of birth control

        Exclusion Criteria:

          -  Positive results for Hepatitis B, Hepatitis C, or HIV

          -  Frequent use of tobacco products, including cigarettes, cigars, chewing tobacco

          -  A medical history of significant hematological, gastrointestinal, respiratory, renal,
             hepatic, cerebrovascular, immunologic, psychiatric or cardiovascular disease or event;
             Current or recent respiratory infection

          -  Presence or history of significant allergy

          -  Clinically significant abnormalities noted on ECG

          -  Screening vital signs representing sustained elevated blood pressure

          -  Presence of significant gastrointestinal abnormalities

          -  Safety laboratory abnormalities noted at screening which are clinically significant

          -  Current or defined history of abuse of alcohol or illicit drugs

          -  A positive pregnancy test at screening

          -  Poor vein access or fear of venipuncture or sight of blood
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Matson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prism Research, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2014</study_first_submitted>
  <study_first_submitted_qc>April 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2014</study_first_posted>
  <last_update_submitted>July 14, 2016</last_update_submitted>
  <last_update_submitted_qc>July 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioavailability Study</keyword>
  <keyword>Aviragen Therapeutics, Inc.</keyword>
  <keyword>Aviragen Therapeutics</keyword>
  <keyword>Aviragen</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

